AddThis

Takeda unit starts trial of lymphoma drug

Millennium initiates phase-3 trial of MLN8237

CAMBRIDGE, Mass. — Takeda Pharmaceutical's cancer drug unit has started a late-stage clinical trial of a drug for treating a rare form of lymphoma, the company said.

The unit, Millennium, announced the start of a phase-3 trial to evaluate MLN8237 in patients with relapsed or refractory peripheral T-cell lymphoma, an aggressive non-Hodgkin's lymphoma.

"There is a significant unmet need for patients suffering from PTCL," Millennium chief medical officer Karen Ferrante said. "MLN8237 is being explored across a broad range of hematological malignancies and solid tumors. The initiation of this trial represents another major achievement in advancing the Millennium pipeline."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

© 2014 Drug Store News. All Rights Reserved.